24/7 Market News Snapshot 20 March, 2025 – OptiNose, Inc. Common Stock (NASDAQ:OPTN)
DENVER, Colo., 20 March, 2025 (247marketnews.com) – (NASDAQ:OPTN) are discussed in this article.
OptiNose, Inc. (OPTN) has experienced a remarkable surge in its stock price today, opening at $6.426 and soaring to a high of $9.275, marking an impressive increase of 54.58%. This upward movement follows a previous closing price of $6.00 and has drawn significant interest from investors, evidenced by a current trading volume of 670.65K shares. The strong market activity indicates a bullish trend, cementing OPTN as a compelling option in the healthcare sector.
In a significant development, Paratek Pharmaceuticals has announced a merger agreement with OptiNose, aiming to enhance its portfolio with Optinose’s pioneering product, XHANCE® (fluticasone propionate). Valued at up to $330 million, this strategic acquisition is designed to expand access to XHANCE among specialists and primary care providers, targeting approximately 10 million patients affected by chronic rhinosinusitis (CRS). The agreement offers OptiNose shareholders up to $14 per share, including a notable upfront cash payment of $9 per share, which signifies a 50% premium on OptiNose’s closing price as of March 19, 2025.
XHANCE, recognized for its innovative drug-device combination, effectively targets inflammation within the nasal cavity and has become a vital treatment for CRS patients, both with and without nasal polyps. A recent label expansion of XHANCE in 2024 has further broadened its market reach, positioning Paratek to capitalize on new opportunities through its robust commercial infrastructure.
Dr. Evan Loh, CEO of Paratek, expressed optimism about the merger, emphasizing the potential for enhanced adoption of XHANCE in primary care, thereby improving access for numerous patients. Dr. Ramy Mahmoud, CEO of OptiNose, echoed these sentiments, asserting that the collaboration with Paratek will significantly amplify the medicinal impact of XHANCE. With approval from both companies’ boards, the merger is anticipated to close by mid-2025, pending customary conditions, underscoring a shared commitment to innovative healthcare solutions.